12月8日晚，广东皮阿诺科学艺术家居股份有限公司（002853.SZ，下称"皮阿诺"）发布公告称，公司控股股东、实际控制人马礼斌正在筹划控制权变更 事宜，可能导致公司实际控制人发生变更。公司股票自12月9日开市起停牌，预计停牌时间不超过2个交易日。 值得注意的是，在公告发布当日，皮阿诺便提前收获涨停板，收盘价报16.24元/股，股价创近八个月新高，市值达到29.71亿元。 张力制图 营收持续下滑 据悉，皮阿诺作为一家定制家居上市公司，主要从事中高端定制橱柜、衣柜、门墙及其配套家居产品的研发、设计、生产、销售、安装与售后等服务。 近年来，受地产周期影响显著，公司营收连续下滑，且出现亏损。 2024年，公司全年营业收入为8.86亿元，同比大幅下降32.68%，跌至2017年水平；归母净利润为-3.75亿元，同比暴跌535.88%。 2025年前三季度，公司实现营收4.20亿元，同比再降37.27%，延续下滑趋势；归母净利润为-752.52万元，同比下滑191.47%，但较上半年亏损1257.64万 元，幅度有所收窄。 就整体行业来看，由于定制家居行业与房地产产业链深度绑定，地产行业下行，家居定制企业均受到较大影响 ...

读客文化经过多年发展，已建立起从内容策划到市场发行的完整产业能力，形成了独特的商业模式。此 次控股股东层面的调整，有望为读客文化带来新的发展视角和资源支持。一方面，新的治理结构有助于 公司更好把握行业发展趋势，优化业务布局；另一方面，也为公司开拓新的增长领域提供了可能。通过 引入更具协同效应的战略资源，读客文化可望在保持内容创作核心优势的同时，拓展更多元的价值实现 路径。这一主动作为体现了公司管理层的远见和对股东权益的重视。 读客文化控股股东主动筹划控制权变更，这一市场化举措展现了公司积极应对行业挑战、寻求更大发展 空间的决心。在当前文化内容行业转型升级的关键时期，此类主动调整对企业的长期发展具有积极意 义。 12月22日晚间，读客文化（301025）发布公告称控股股东及实际控制人华楠先生、华杉先生正在筹划公 司控制权变更相关事宜，整体方案仍在协商，交易各方尚未签署正式协议，公司股票目前正在停盘阶 段。 ...

停牌2个交易日后，旭升集团（SH603305，股价14.58元，市值169亿元）在12月23日复牌，该公司同步发布公告，称控股股东、实际控制人徐旭东及其一 致行动人签署《控制权收购协议》《股份转让协议》，拟引入广州工业投资控股集团有限公司（以下简称广州工控集团）作为新的控股股东，交易定价接 近43亿元，交易完成后公司实控人将变更为广州市人民政府。 《每日经济新闻》记者查询发现，去年10月，徐旭东也曾宣布筹划旭升集团控制权变更计划，不过最终因"双方就其中某些核心条款始终未能达成一致意 见"，徐旭东决定终止控制权变更事项。 旭升集团主营精密铝合金汽车零部件和工业零部件加工业务，很早便进入特斯拉供应链（特斯拉为公司第一大客户），2017年上市后营收、净利润曾保持 平稳增长势头，但2024年出现营收、净利润双下滑。对此，还有投资者在交流会中就 "行业产销量均为稳步增长，公司业绩却出现下滑" 提出疑问。 对于此次与广州国资的交易，徐旭东方面就旭升集团2026年至2028年扣非归母净利润作出业绩承诺为"累计不低于15亿元"，且双方还约定"若完成12亿元 则不触发业绩补偿义务"。记者计算发现，2022年至2024年，旭升集 ...

今年前三季度，公司营收2.57亿元，同比下滑12.19%；归母净利润仅652.10万元，同比大幅下降 56.72%。不仅如此，公司现金流压力凸显，经营活动产生的现金流量净额为-794.38万元。为提振业 绩，公司加大了抖音、小红书、视频号等平台的投流支出，导致销售费用同比增长24.10%至3772.66万 元，但从业绩来看，上述营销投入尚未在收入端显现成效。 值得注意的是，在本次控制权变更筹划前，实控人的一致行动人已开启持续减持。 2025年1月，宁波读客公告计划减持不超过1120万股，占公司总股本比例不超过2.80%；5月完成累计 1119.09万股减持，套现金额达1.03亿元；11月再次通过询价转让方式减持410.82万股，套现3438.55万 元。加上2023年原核心高管朱筱筱累计减持约6051万元，公司相关主体累计套现超2亿元，已超过读客 文化上市至今的利润总和。 股权结构层面，华楠、华杉兄弟长期保持对读客文化的绝对控制。截至2025年三季度末，华楠直接持股 41.02%，华杉直接持股29.58%，二人共同控制的宁波读客持有1.31%股份，合计共控制公司71.91%的股 份。 此次控制权变更或与公司业 ...

【导读】旭升集团控股股东又筹划控制权变更事项，自12月19日开市起停牌 12月18日，旭升集团接到徐旭东的通知，徐旭东及其一致行动人宁波梅山保税港区旭晟控股有限公司（以下简称旭晟控 股）、香港旭日实业有限公司（以下简称旭日实业），正在筹划涉及所持旭升集团股份转让事宜，可能导致旭升集团控制 权变更。 控股股东时隔一年又筹划控制权转让事项 12月18日晚间，旭升集团发布公告称，公司控股股东、实际控制人徐旭东及其一致行动人正在筹划涉及所持公司股份转让 事宜，可能导致公司控制权变更。 旭升集团计划自12月19日开市起停牌，预计停牌时间不超过2个交易日。截至12月18日收盘，旭升集团股价报14.56元/股， 总市值为168.3亿元。 | 证券代码 | 证券简称 | 停复牌类型 | 停牌起始日 | 停牌 期间 | 停牌终止日 | 复牌日 | | --- | --- | --- | --- | --- | --- | --- | | 603305 | 旭升集团 | A 股 停牌 | 2025/12/19 | | | | 这是时隔一年多，徐旭东及其一致行动人再次筹划相关事项。 2024年10月29日，旭升集团接到徐旭东的通知 ...

东方智造控制权或生变，广西国资拟接盘 东方智造在公告中表示，公司于12月14日收到控股股东科翔高新的通知，后者正在筹划涉及其所持有公司股份转让事宜，其拟将持有占公司总股本约 14.33%的股份转让给广西现代物流集团有限公司（以下简称"广西物流"）或其指定主体，可能导致公司控制权发生变更。 12月15日，东方智造（SZ002175， 股价4.34元，市值54.90亿元）发布停牌公告，公司控股股东科翔高新技术发展有限公司（以下简称"科翔高新"）拟将持 有占公司总股本约14.33%的股份转让给广西现代物流集团有限公司或其指定主体。 《每日经济新闻》记者（以下简称"每经记者"）查询到，科翔高新成为东方智造控股股东仅4年时间，其持股比例为19.21%。因此若上述交易顺利完成，其 持股比例将降至5%以内。 4年前，科翔高新以重整投资人身份成为东方智造控股股东，并作出"重整计划执行完毕后三个会计年度上市公司经审计的净利润（以扣非前后孰低者为准） 合计不低于2.5亿元"的承诺。 遗憾的是，东方智造2022年至2024年合计实现净利润（以扣非前后孰低者为准）约3885万元，远低于2.5亿元的承诺额，触发业绩补偿。但科翔高新并未 ...

Core Viewpoint - The actual controller of Xinyaqiang (603155.SH), a leader in the silicone industry, has changed to the Handan State-owned Assets Supervision and Administration Commission following a share transfer agreement with the Handan City Chengxin Equity Investment Fund for 1.96 billion yuan [3][6]. Shareholder Changes - On November 25, Xinyaqiang announced that the Handan Chengxin Equity Investment Fund acquired 94.42 million shares from the previous major shareholder, Chu Lin, for 20.76 yuan per share, representing a premium of approximately 15.2% over the closing price on the announcement date [3][5][8]. - After the transfer, the Chengxin Fund will hold 29.9% of Xinyaqiang's total shares, making it the largest shareholder, while Chu Lin's stake will decrease to 16.09% [5][6]. Company Background - Xinyaqiang, established in 1992 and listed on the Shanghai Stock Exchange in September 2020, specializes in silicone functional additives and phenyl chlorosilane, with its products integrated into the semiconductor and new energy supply chains [7][8]. - The company's core product, hexamethyldisilazane, is recognized as a key material in chip photolithography processes [7]. Industry Context - The change in control comes amid a supply-demand adjustment in the silicone industry, with companies planning a 30% production cut starting in December [8][9]. - Xinyaqiang's performance has been declining, with a significant drop in revenue and net profit since 2022 due to rapid capacity expansion in the industry [8][9][12]. Financial Performance - Xinyaqiang's revenue and net profit have fluctuated significantly over the past few years, with a peak in 2021 followed by a decline in subsequent years. For instance, the net profit for 2024 is projected at 114 million yuan, down over 60% from the 2021 peak [9][12]. - The company's gross margin has also decreased from 43.15% in 2021 to 20.77% in 2024 [9]. Management Transition - The transition of control is linked to challenges in management succession and declining performance. Initial leadership changes occurred in 2023, but the transition has not been smooth [13][14]. - The Handan Chengxin Fund has committed to maintaining control for at least 18 months and will not transfer control for seven years after acquiring it [16].

Core Viewpoint - Shenzhen Gongjin Electronics Co., Ltd. is undergoing a change in control, with Tangshan Industrial Holding Group becoming the new controlling shareholder, and the Tangshan Municipal Government's State-owned Assets Supervision and Administration Commission becoming the actual controller [1][2] Group 1: Control Change Announcement - The major shareholder and actual controller will change, with Tangshan Industrial Holding Group acquiring 88.06 million shares (11.18% of total equity) at a price of 10.75 yuan per share, totaling 947 million yuan [1] - After the transaction, Tangshan Industrial Holding Group will hold 26.10% of the voting rights, making it the controlling shareholder [1] Group 2: Business Operations and Financial Performance - The transaction is subject to approval from state-owned asset supervision authorities, antitrust review, and compliance confirmation from the Shanghai Stock Exchange [2] - In the first three quarters of 2025, the company reported a significant improvement in performance, with revenue of 6.539 billion yuan, a year-on-year increase of 8.15%, and a net profit of 86 million yuan, up 529.94% year-on-year [2] - The increase in performance is attributed to improved profitability, with a gross margin of 11.99%, up 0.25 percentage points year-on-year, and a decrease in expense ratio by 1.99 percentage points [2] - The company's overseas business revenue grew by over 40% year-on-year, accounting for over 70% of total revenue, indicating strong overseas development momentum [2] - The second phase of the factory in Vietnam has been successfully put into production, and the North American cooperative factory project is progressing [2]

Core Viewpoint - Delong Huineng (000593.SZ) experienced a stock price surge following the announcement of a change in control, with shares closing at 9.58 yuan, marking a significant market reaction to the news of a new major shareholder [1] Summary by Sections Shareholder Change - Delong Huineng announced that its controlling shareholder, Beijing Dingxin Ruitong Technology Development Co., Ltd., signed a share transfer agreement with Dongyang Noxin Chip Material Enterprise Management Partnership (Limited Partnership), transferring 106 million shares, representing 29.64% of the total share capital, for a total consideration of 1 billion yuan at a price of 9.41 yuan per share [1][2] - After the transfer, Noxin Chip Material will hold 29.64% of the shares, while Dingxin Ruitong's stake will decrease to 2.36% [1][3] Background of New Shareholder - Noxin Chip Material was established on July 24, 2025, with a registered capital of 1.008 billion yuan and has not yet commenced business operations [3] - The ultimate control of Noxin Chip Material lies with Sun Weijia, who also controls other semiconductor-related enterprises, suggesting potential strategic moves in the semiconductor sector following the acquisition [4][7] Historical Context of Delong Huineng - Delong Huineng has undergone four ownership changes since its listing, with its business focus shifting multiple times, originally starting as a retail company before transitioning to pharmaceuticals and then to gas and energy [8][9] - The company was renamed from Datong Gas to Delong Huineng in 2022, reflecting its current focus on integrating traditional gas operations with new energy initiatives, including hydrogen and solar energy [9][11] Financial Performance - Despite revenue growth from 631 million yuan in 2018 to 1.737 billion yuan in 2024, the company has faced challenges in profitability, with cumulative losses of 208 million yuan during the same period [11] - The company is currently involved in legal proceedings regarding a subsidiary's failure to meet profit commitments, which may impact its financial stability [11]

Core Viewpoint - The control rights of two pharmaceutical companies, Asia-Pacific Pharmaceutical and Duori Pharmaceutical, are set to change, indicating a rapid reshuffling in the pharmaceutical industry [1][2]. Group 1: Control Changes - Asia-Pacific Pharmaceutical's controlling shareholder will change from Ningbo Fubon Holding Group to Zhejiang Xinghao Holding Partnership, which will acquire 14.61% of the shares [2][3]. - Duori Pharmaceutical's controlling shareholder will shift from Tibet Jiakang Times Technology Development to a group led by Wang Qingtai, Cui Zihao, and Cao Xiaobing, who will collectively hold 29.60% of the shares [2][6]. - The actual control of Asia-Pacific Pharmaceutical will transition from a management team to Qiu Zhongxun, while Duori Pharmaceutical's control will shift from Deng Yong to the new group [2][6]. Group 2: Stock Performance - On the first trading day after the announcement, Asia-Pacific Pharmaceutical's stock hit the daily limit, closing at 6.24 yuan per share, with a market capitalization of approximately 4.653 billion yuan [2][3]. - Duori Pharmaceutical opened high and saw an intra-day increase of 13.40%, closing at 42.06 yuan per share, with a market capitalization of about 3.365 billion yuan [2][3]. Group 3: Financial Transactions - Asia-Pacific Pharmaceutical's share transfer agreement involves a total of 1.09 billion shares at a price of 8.26 yuan per share, totaling 900 million yuan, reflecting a premium of 45.68% over the previous closing price [3][4]. - Duori Pharmaceutical's share transfer involves 2.368 million shares at a price of 32.064 yuan per share, totaling 759 million yuan [6][7]. Group 4: Financial Performance - Asia-Pacific Pharmaceutical reported a revenue of 405 million yuan in 2024, a decrease of 3.68% year-on-year, with a continued decline in the first half of the year, showing a 31.48% drop [5][6]. - The company has recorded six consecutive years of losses in net profit attributable to shareholders, with a significant loss of 4.9 billion yuan in the first half of this year [5][6]. - Duori Pharmaceutical's revenue has also seen a decline for three consecutive years, with 2022-2024 revenues of 401 million yuan, 334 million yuan, and 241 million yuan, respectively [8].